Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Scientists solve the mystery of 'impossible' merger of 'forbidden' black holes - 2Internet goes (cocoa) nuts: The funniest reactions to 12 tonne theft of KitKat bars
- 3Great DSLR Cameras for Photography Devotees
- 4Lockheed Martin opens new hypersonic weapons facility
- 5The most effective method to Examine a Cellular breakdown in the lungs Finding with Family
- Reality TV star Spencer Pratt, who lost his home in Palisades Fire, is running for mayor of Los Angeles
- ‘More should be done’: UN pushes Syrian regime on justice for Druze, Alawites and minority groups
- Syria rejects forced deportations from Germany amid migration debate
- Holiday spots Well known With Americans In 2024
- Instructions to Pick the Right Dental Embed Trained professional: An Exhaustive Aide
- Von der Leyen: Paris meeting sends signal of unity for Ukraine
- Find Serenity: 10 Stunning Setting up camp Areas
- We may have one thing in common with jellyfish, new research finds
- Hundreds of kilos of protected plant seized by Israel Nature and Parks Authority in Golan
